Sunday, December 28, 2008

Scientists plan to ignite tiny man-made star


Jeff Wisoff, deputy principal associate director of the NIF, in the room where a single infrared laser is sent through almost a mile of lenses, mirrors and amplifiers.


The capsule containing the 'fuel' on which laser beams will be concentrated. The aim is to generate temperatures of more than 1,000 million degrees Celsius.

man-made sun: National Ignition Facility (NIF), California
Inside the target chamber, where scientists will attempt to create an artificial sun.

It is science’s star experiment: an attempt to create an artificial sun on earth — and provide an answer to the world’s impending energy shortage.

While it has seemed an impossible goal for nearly 100 years, scientists now believe that they are on brink of cracking one of the biggest problems in physics by harnessing the power of nuclear fusion, the reaction that burns at the heart of the sun.

In the spring, a team will begin attempts to ignite a tiny man-made star inside a laboratory and trigger a thermonuclear reaction.

Its goal is to generate temperatures of more than 100 million degrees Celsius and pressures billions of times higher than those found anywhere else on earth, from a speck of fuel little bigger than a pinhead. If successful, the experiment will mark the first step towards building a practical nuclear fusion power station and a source of almost limitless energy.

At a time when fossil fuel supplies are dwindling and fears about global warming are forcing governments to seek clean energy sources, fusion could provide the answer. Hydrogen, the fuel needed for fusion reactions, is among the most abundant in the universe. Building work on the £1.2 billion nuclear fusion experiment is due to be completed in spring.

Scientists at the National Ignition Facility (NIF) in Livermore, nestled among the wine-producing vineyards of central California, will use a laser that concentrates 1,000 times the electric generating power of the United States into a billionth of a second.

The result should be an explosion in the 32ft-wide reaction chamber which will produce at least 10 times the amount of energy used to create it.

"We are creating the conditions that exist inside the sun," said Ed Moses, director of the facility. "It is like tapping into the real solar energy as fusion is the source of all energy in the world. It is really exciting physics, but beyond that there are huge social, economic and global problems that it can help to solve."

Inside a structure covering an area the size of three football pitches, a single infrared laser will be sent through almost a mile of lenses, mirrors and amplifiers to create a beam more than 10 billion times more powerful than a household light bulb.

Housed within a hanger-sized room that has to be pumped clear of dust to prevent impurities getting into the beam, the laser will then be split into 192 separate beams, converted into ultraviolet light and focused into a capsule at the centre of an aluminium and concrete-coated target chamber.

When the laser beams hit the inside of the capsule, they should generate high-energy X-rays that, within a few billionths of a second, compress the fuel pellet inside until its outer shell blows off.

This explosion of the fuel pellet shell produces an equal and opposite reaction that compresses the fuel itself together until nuclear fusion begins, releasing vast amounts of energy.

Scientists have been attempting to harness nuclear fusion since Albert Einstein’s equation E=mc², which he derived in 1905, raised the possibility that fusing atoms together could release tremendous amounts of energy.

Under Einstein’s theory, the amount of energy locked up in one gram of matter is enough to power 28,500 100-watt lightbulbs for a year.

Until now, such fusion has only been possible inside nuclear weapons and highly unstable plasmas created in incredibly strong magnetic fields. The work at Livermore could change all this.

The sense of excitement at the facility is clear. In the city itself, people on the street are speaking about the experiment and what it could bring them. Until now Livermore has had only the dubious honour of being home of the US government’s nuclear weapons research laboratories which are on the same site as the NIF.

Inside the facility, the scientists are impatient. After 11 years of development work, they want the last of the lenses and mirrors for the laser to be put in place and the tedious task of adjusting and aiming the laser to be over, a process they fear could take up to a year before they can successfully achieve fusion.

Jeff Wisoff, a former astronaut who is deputy principal associate director of science at the NIF, said: "Everyone is keen to get started, but we have to get the targeting right, otherwise it won’t work.

"We will be firing laser pulses that last just a few billionths of a second but we will be creating conditions that are found in the interior of stars or exploding nuclear weapons.

"I worked on the building of the International Space Station, but this is a far bigger challenge and the implications are huge. When we started the project, a lot of the technology we needed did not exist, so we have had to develop it ourselves.

"The next step is looking at how ignition can be used to deliver something of value to the world. It has the potential to be one of the biggest achievements mankind has made."

Although other experiments have attempted to create the conditions needed for nuclear fusion, lasers are seen as the most likely technique to be able to provide a viable electricity supply.

If all goes well, the NIF will be able to fire its laser and ignite a fusion reaction every five hours, but to create a reliable fusion power plant the laser would need to ignite fusion around 10 times a second.

The scientists are already working with British counterparts on the next step towards a fusion power station. A project known as the High Powered Laser Research facility aims to create a laser-powered fusion reactor that can fire once every couple of minutes.

Prof Mike Dunne, director of the central laser facility at the Rutherford Appleton Laboratory near Oxford, said: "The National Ignition Facility is going to finally prove fusion can be achieved with a laser. It will start an exciting new period in physics as it will prove what we are trying to achieve is actually be possible."

Source

Targeted Nanoparticles Deliver Therapeutic DNA to Cancer Cells

12/25/2008 11:22:47 PM

Given that cancer is a disease caused by gene mutations, cancer researchers have been striving to develop gene therapies aimed at correcting these mutations. However, these efforts have been hobbled by the difficulty in safely and efficiently delivering anticancer genes to tumors. Nanoparticles, however, may solve these delivery issues, and two recently published studies, using two different types of nanoparticles, lend credence to that hypothesis.

Miqin Zhang, Ph.D., PI of the Nanotechnology Platform for Pediatric Brain Cancer Imaging and Therapy project at the University of Washington in Seattle, led a group of researchers that developed a targeted polymer nanoparticle that efficiently delivered a model gene into two types of cancer cells. More importantly, the gene functions properly once it enters the targeted cells. In the second study, Mansoor Amiji, Ph.D., PI of the Nanotherapeutic Strategy for Multidrug Resistant Tumors Platform Partnership at Northeastern University, and doctoral student Padmaja Magadala, M.S., used gelatin-based nanoparticles and a different targeting agent to efficiently deliver the same model gene to human pancreatic tumor cells. As in the first study, the delivered gene functioned properly inside the tumor cells.

The nanoparticle developed by Dr. Zhang’s group was made of two polymers—polyethyleneimine (PEI) and polyethylene glycol (PEG)—linked to chlorotoxin, a small protein isolated from scorpion venom. Previous research by several research teams had shown that chlorotoxin binds many types of tumors, including gliomas and medulloblastomas, two types of brain cancer. PEI forms stable nanoparticles that bind deoxyribonucleic acid (DNA), but the resulting nanoparticles can be toxic. Adding PEG to the nanoparticles provides a biocompatible surface that greatly reduces the toxicity of PEI.

As a test, Dr. Zhang and her colleagues used these nanoparticles to deliver DNA that codes for green fluorescent protein (GFP), which is used widely to study gene expression. When added to tumor cells expressing the chlorotoxin receptor, the nanoparticles were quickly taken up by the cells. The cells also turned green, thanks to the expression of GFP. In contrast, nanoparticles lacking chlorotoxin were not taken up by the cells, and tumor cells lacking the chlorotoxin receptor did not take up the nanoparticles.

(The three scientists credited with discovering and developing GFP as a critical research tool were awarded the 2008 Nobel Prize in Chemistry. One of those scientists, Roger Tsien, Ph.D., is an investigator at NCI’s Center of Nanotechnology for Treatment, Understanding, and Monitoring of Cancer at the University of California, San Diego.)

Dr. Amiji’s approach differed, in that he used a peptide that targets the epidermal growth factor receptor that is overexpressed by several types of tumors, including pancreatic cancer. He also used a nanoparticle constructed from negatively charged gelatin, which readily incorporates DNA and other nucleic acids, which are positively charged at normal physiological pH. The structure of the nanoparticle material also promotes DNA to take on a supercoiled structure that is efficiently taken up and transported to the cell’s nucleus, a critical factor for gene expression to occur. To improve the biocompatibility of these nanoparticles, Dr. Amiji also used PEG to coat the nanoparticles.

When added to pancreatic cells, nearly half of the administered dose of these engineered, targeted nanoparticles were taken up by pancreatic tumor cells, a remarkably high value. More importantly, a large percentage of the transfected cells subsequently expressed GFP. In addition, the nanoparticles were not toxic to the cells, an important finding given that they did not contain any therapeutic agent.

The work from Dr. Zhang’s group, which was detailed in the paper “A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells,” was supported by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer. An abstract of this paper is available at the journal’s Web site.

View abstract

The study headed by Dr. Amiji, which was described in the paper “Epidermal growth factor receptor-targeted gelatin-based engineered nanocarriers for DNA delivery and transfection in human pancreatic cancer cells,” was also supported by the NCI Alliance for Nanotechnology in Cancer. An abstract of this paper is available at the journal’s Web site.

View abstract.


Source

Friday, December 26, 2008

Better Than Phelps: Nanowires Zap Cancer



This image depicts several cells coated with fluorescent dyes making them appear red. Three nanowires – the neon green lines – have successfully attached themselves to the cells. When a low frequency electromagnetic field is applied, the nanowires heat up and destroy the attached cells.
Category: College of Engineering Date: 12/18/2008





Better Than Phelps: Hot, Golden, Swimming Nanowires Zap Cancer

Dec. 18, 2008

Image is available at www.today.uidaho.edu/PhotoList.aspx

Written by Ken Kingery

MOSCOW, Idaho – The next big thing in cancer treatment may be hotter, covered in more gold, and even be a better swimmer than recent Olympic champion Michael Phelps.

Scientists at the University of Idaho are engineering multifunctional and dynamic nanowires coated in gold that swim through the bloodstream and attach to specific cancerous cells. Once there, an electromagnetic field heats the nanowires, which destroys the targeted cells. The research is supported by a new $425,000 grant, part of a multimillion dollar project funded by the Korean government as part of the International Global Collaboration Pioneer Program.

“Cancer is a dangerous enemy because radiation and chemical treatments cause a lot of side effects,” said Daniel Choi, associate professor of materials science and engineering at the University of Idaho and leader of the project. “We can’t avoid side effects 100 percent, but these nanowires will minimize the damage to healthy cells.”

The technology involves many steps requiring lots of continuing research, but each of the basic concepts already have been proven in laboratory tests.

Choi and his team have already created nanowires that can “swim” to their targets and heat up when exposed to low frequency electromagnetic fields, which are not harmful to human body. The next step is to make them biocompatible, meaning safe to introduce to the human body, and able to seek out specific cancer cells.

Choi believes the gold plating will take care of the biocompatibility. If not, he has several polymers in mind that he also believes would work.

As for seeking out specific cancer cells, Choi also is a member of and working with a University of Idaho group called BANTech – an interdisciplinary group that integrates nanomaterials research with cell biology and bioscience research. The group has identified several promising candidates for antibodies with which to coat the nanowires that would seek out and attach to specific cancer cells.

Once the technology has proven itself in the laboratory, it will be tested in live animals, and eventually human beings. Several Korean institutions, which are helping in every phase of research, will take the lead in that project. The institutions are Seoul National University, Korea University and the Korea Institute of Science and Technology.

“Collaborating with Korean institutions has been a wonderful experience full of mutual benefits and great achievements,” said Choi. “Multi-institutional, multi-national projects can provide students and researchers with opportunities to engage in cutting-edge investigations within an international research environment, which is very important to advancing science.”

# # #

About the University of Idaho

Founded in 1889, the University of Idaho is the state’s flagship higher-education institution and its principal graduate education and research university, bringing insight and innovation to the state, the nation and the world. University researchers attract nearly $100 million in research grants and contracts each year; the University of Idaho is the only institution in the state to earn the prestigious Carnegie Foundation ranking for high research activity. The university’s student population includes first-generation college students and ethnically diverse scholars. Offering more than 150 degree options in 10 colleges, the university combines the strengths of a large university with the intimacy of small learning communities. For information, visit www.uidaho.edu.

Media Contact: Ken Kingery, University Communications, (208) 885-9156, kkingery@uidaho.edu

Source

Hyperthermia with Magnetic Nanowires for Inactivating Living Cells

D. S. Choi1 ∗, J. Park2, S. Kim2, D. H. Gracias2, M. K. Cho3, Y. K. Kim3†, A. Fung4,
S. E. Lee5, Y. Chen4, S. Khanal1, S. Baral1, and J.-H. Kim1
1Department of Materials Science and Engineering, University of Idaho, Moscow, ID 83844
2Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD 21218, USA
3Department of Materials Science and Engineering, Korea University, Seoul 136-713, Korea
4Department of Biomedical Engineering, University of California, Los Angeles, CA 90095, USA
5Department of Mechanical and Aerospace Engineering, University of California, Los Angeles, CA 90095, USA

We describe a method to induce hyperthermia in cells, in-vitro, by remotely heating Ni nanowires (NWs) with radio frequency (RF) electromagnetic fields. Ni NWs were internalized by human embryonic kidney cells (HEK-293). Only cells proximal to NWs or with internalized NWs changed shape on exposure to RF fields indicative of cell death. The cell death occurs as a result of hyperthermia, since the RF field remotely heats the NWs as a result of magnetic hysteresis. This is the first demonstration of hyperthermia induced by NWs; since the NWs have anisotropic and strong magnetic moments, our experiments suggest the possibility of performing hyperthermia at lower field strengths in order to minimize damage to untargeted cells in applications such as the treatment of cancer.

Source



Daniel S. Choi, Ph.D.

BANTech

Thursday, December 25, 2008

(WO/2008/156504) SELF-ASSEMBLED NANOPARTICLES - NANOTUBE STRUCTURES BASED ON ANTENNA CHEMISTRY OF CONDUCTIVE NANORODS

Link
Latest bibliographic data on file with the International Bureau
Pub. No.: WO/2008/156504 International Application No.: PCT/US2007/088428
Publication Date:24.12.2008 International Filing Date:20.12.2007
IPC: B81B 3/00 (2006.01)
Applicants:WILLIAM MARSH RICE UNIVERSITY [US/US]; 6100 Main Street, Houston, TX 77005 (US) (All Except US).
SCHMIDT, Howard, K. [US/US]; (US) (US Only).
DUQUE, Juan, G. [US/US]; (US) (US Only).
PASQUALI, Matteo [IT/US]; (US) (US Only).
Inventors:SCHMIDT, Howard, K.; (US).
DUQUE, Juan, G.; (US).
PASQUALI, Matteo; (US).
Agent:SHADDOX, Robert, C.; Winstead PC, P.O. Box 50784, Dallas, TX 75201 (US).
Priority Data:
60/875,907 20.12.2006 US
60/991,052 29.11.2007 US
61/007,061 11.12.2007 US
Title: SELF-ASSEMBLED NANOPARTICLES - NANOTUBE STRUCTURES BASED ON ANTENNA CHEMISTRY OF CONDUCTIVE NANORODS
Abstract:
The present invention relates in general to nanostructured materials and processes for making same. More particularly, the present inventions relates to a nanoscale composite structure and methods for making same involving a conductive nanorod comprising a tip at each of the nanorod extrema; and a material deposited on at the least the tips, wherein the material comprises a reduced form of a redox species, wherein the redox species is adapted for electrochemical reaction with the conductive nanorod when the conductive nanorod is stimulated as an antenna by an electric field.


[0047] The present inventors observed clear evidence that SWNT behave as antennas in the presence of light, microwaves and radio frequency fields. The present inventors also found a mechanism to produce high yields of SWNT rings and novel split-ring structures. The present inventors contemplate that these results support the idea that EM-stimulated therapies based on SWNT antennas are possible, and that tunable structures may be developed to optimize RF thermoablation therapies.

[0048] The present inventors anticipate that using SWNT, or similar elongated conductive particles, to generate free radicals in solution may be useful for a variety of applications. By way of example and not limitation, one application may be as a cytotoxic agent in healthcare. In conjunction with a targeting, or localization process, the present process may include stimulating the SWNT with body-penetratine electric fields to generate high concentrations of ROS (Reactive Oxygen Species). These may then have a toxic effect on local tissues. The fields may be localized further by using phased array electro-magnetic sources. This field emission mediated process may be non-linearly dependent (as all field emission processes, described by Fowler-Nordheim i-v curves are) on the applied field and the length of the antennas (length of SWNT). Further the present inventors expect that controlled precipitation/bundling of SWNT (by targeting multiple SWNT to a given target cell) may 'construct' antennae long enough to produce ROS, while individual SWNT may remain essentially inert under electric stimulation. By one or a combination of these means, the present process and nanostructured materials may readily achieve a very selective agent for destroying undesirable tissues, e.g. cancer, perhaps even at the level of individual cells. This may tend to be more desirable than the generalized cytotoxins or radiation-based treatments commonly used today.

Source

Wednesday, December 24, 2008

This Machine Might* Save the World

* that's a big, fat "might"

Two desktop-printer engineers quit their jobs to search for the ultimate source of endless energy: nuclear fusion. Could this highly improbable enterprise actually succeed?

Monday, December 22, 2008

USC researchers print dense lattice of transparent nanotube transistors on flexible base

Public release date: 16-Dec-2008
[ Print Article | E-mail Article | Close Window ]

Contact: Eric Mankin
mankin@usc.edu
213-821-1887
University of Southern California

Low-temperature process produces both n-type and p-type transistors; allows embedding of LEDs

IMAGE: See-through circuit makers: Hsaioh-Kang Chang, left, and Fumiaki Ishikawa, with their transparent, flexible transistor array.

Click here for more information.

It's a clear, colorless disk about 5 inches in diameter that bends and twists like a playing card, with a lattice of more than 20,000 nanotube transistors capable of high-performance electronics printed upon it using a potentially inexpensive low-temperature process.

Its University of Southern California creators believe the prototype points the way to such long sought after applications as affordable "head-up" car windshield displays. The lattices could also be used to create cheap, ultra thin, low-power "e-paper" displays.

They might even be incorporated into fabric that would change color or pattern as desired for clothing or even wall covering, into nametags, signage and other applications.

A team at the USC Viterbi School of Engineering created the new device, described and illustrated in a just-published paper on "Transparent Electronics Based on Printed Aligned Nanotubes on Rigid and Flexible Structures" in the journal ACS Nano.

Graduate students Fumiaki Ishikawa and Hsiaoh-Kang Chang worked under Professor Chongwu Zhou of the School's Ming Hsieh Department of Electrical Engineering on the project, solving the problems of attaching dense matrices of carbon nanotubes not just to heat-resistant glass but also to flexible but highly heat-vulnerable transparent plastic substrates.

The researchers not only created printed circuit lattices of nanotube-based transistors to the transparent plastic but also additionally connected them to commercial gallium nitrate (GaN) light-emitting diodes, which change their luminosity by a factor of 1,000 as they are energized.

"Our results suggest that aligned nanotubes have great potential to work as building blocks for future transparent electronics," say the researchers.

The thin transparent thin-film transistor technology developed employs carbon nanotubes - tubes with walls one carbon atom thick - as the active channels for the circuits, controlled by iridium-tin oxide electrodes which function as sources, gates and drains.

Earlier attempts at transparent devices used other semiconductor materials with disappointing electronic results, enabling one kind of transistor (n-type); but not p-types; both types are needed for most applications.

The critical improvement in performance, according to the research, came from the ability to produce extremely dense, highly patterned lattices of nanotubes, rather than random tangles and clumps of the material. The Zhou lab has pioneered this technique over the past three years.

The paper contains a description of how the new devices are made.

"These nanotubes were first grown on quartz substrates and then transferred to glass or PET substrates with pre-patterned indium-tin oxide (ITO) gate electrodes, followed by patterning of transparent source and drain electrodes. In contrast to random networked nanotubes, the use of massively aligned nanotubes enabled the devices to exhibit high performance, including high mobility, good transparency, and mechanical flexibility.

"In addition, these aligned nanotube transistors are easy to fabricate and integrate, as compared to individual nanotube devices. The transfer printing process allowed the devices to be fabricated through low temperature process, which is particularly important for realizing transparent electronics on flexible substrates. … While large manufacturability must be addressed before practical applications are considered, our work has paved the way for using aligned nanotubes for high-performance transparent electronics "

###

Ishikawa and Chang are the principal authors of the paper. Viterbi School graduate students Koungmin Ryu, Pochiang Chen, Alexander Badmaev, Lewis Gomez De Arco, and Guozhen Shen also participated in the project. Zhou, an associate professor, holds the Viterbi School's Jack Munushian Early Career Chair.

The Focus Center Research Program (FCRP FENA) and the National Science Foundation supported the research. The original article can be read at: http://pubs.acs.org/doi/abs/10.1021/nn800434d

Source

Friday, December 19, 2008

Researchers target cancer cells; note treatment by SW Florida resident

By MATT CLARK (Contact)
Steven A. Curley, M.D., right, and John Kanzius, inventor of this radio wave transmitter, check over the machine before a test is run in Erie, Pa.

MICHEL FORTIER / ROB ENGELHARDT/Erie Times-News

Steven A. Curley, M.D., right, and John Kanzius, inventor of this radio wave transmitter, check over the machine before a test is run in Erie, Pa.

Born out of necessity through his own battle with cancer, John Kanzius has developed a technique which may one day eradicate cancer cells in humans with radio waves in a much less invasive fashion than current radiation techniques.

MICHEL FORTIER

Born out of necessity through his own battle with cancer, John Kanzius has developed a technique which may one day eradicate cancer cells in humans with radio waves in a much less invasive fashion than current radiation techniques.

Video

Sanibel Island inventor and cancer patient John Kanzius demonstrates his cancer-fighting machine.

Sanibel Island inventor and cancer patient John Kanzius demonstrates his cancer-fighting machine. Watch video.

They've demonstrated the cancer research "holy grail."

In a manuscript published today, researchers say they have successfully targeted and killed two of the most deadly types of cancer cells, colon and pancreatic, using the treatment invented by Sanibel Island and Erie, Pa. resident John Kanzius.

"This is what everybody's been waiting for," Kanzius said. "Can you target cancer cells? And the answer is 'yes.' Can you kill them? Yes. Can you target specific cancers? Yes."

Though the researchers said the destroyed cancer cells were not in animals or humans, the findings published in the peer-reviewed Journal of Experimental Therapeutics and Oncology have shown once again that a man with no formal medical training -- and who continues his own battle with a rare form of B-cell leukemia -- can develop a treatment capable of killing cancer.

The treatment Kanzius first envisioned in 2003 is hoped to one day go like this:

- A patient will be injected with a solution of small pieces of metal known as nanoparticles, which are attached to lab-created, disease-fighting antibody cells capable of targeting specific cancers.

- The gold nanoparticles, which are so small 75,000 to 100,000 of them can fit across the tip of a human hair, will run through the body, the antibodies attached to them hunting for the specific cancer cells being targeted. Once they find the cancer cells, they burrow inside.

- The patient is then exposed to low-frequency radio waves emitted from the transmitter Kanzius' first designed in the garage of his Sanibel Island home. Somewhat like metal in a microwave, which uses frequencies a million times more powerful to vibrate molecules generating heat, the nanoparticles will heat up, killing the cancer cells, but leaving adjacent cells unharmed.

The researchers working with Kanzius have already demonstrated they can kill cancer cells in laboratory animals using the nanoparticles and radio transmitter while leaving adjacent cells unharmed. Those findings were published Oct. 2007. But those experiments had the nanoparticles injected directly into tumors, not targeted to specific cancer cells -- an accomplishment that has baffled cancer researchers for years.

Lead researcher Dr. Steven Curley, a professor of surgical oncology at M.D. Anderson Cancer Center in Houston, rated No. 1 in cancer treatment by U.S. News and World Report for four of the past six years, told supporters in a letter earlier this month that targeting nanoparticles to specific types of cancers has been accomplished.

"This will be the first manuscript that proves that we can target nanoparticles to a specific abnormality on cancer cells, and increase the killing by getting more nanoparticles into the cells," Curley said.

In the letter, Curley indicated talks with the Food and Drug and Administration are expected to begin soon, possibly within the next few months. When they do, the treatment will be one step closer to human trials, which may occur in months or years.

Also in the coming months, further manuscripts demonstrating the effectiveness in treating leukemia are expected to be released, the letter from Curley said.

Stay tuned to naplesnews.com for additional information on this developing story. In the meantime, examine the Daily News' article and video released in June detailing Kanzius' development of the treatment.

Source

Kanzius concept

BY DAVID BRUCE

david.bruce@timesnews.com [more details]

Published: December 19. 2008 12:01AM

Cick pic to ENLARGE





WHAT IT MEANS
Researchers at M.D. Anderson Cancer Center in Houston have proved they can target cancer cells exclusively and destroy them with John Kanzius' external radio-frequency generator. It clears a significant hurdle in proving the device can successfully treat cancer in humans.
Researchers have shown that they can target cancer cells with tiny pieces of gold and destroy the cells by using John Kanzius' external radio-frequency generator.


The success clears a major hurdle in proving that the Millcreek Township inventor's device can be used to successfully treat cancer in humans.

A scientific article about the targeting will be published today on the Web site of the Journal of Experimental Therapeutics and Oncology. The journal's Web site is www.oldcitypublishing.com/JETO/JETO.html.
[p. 313-326
Noninvasive radiofrequency field-Induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles
Steven A. Curley, Paul Cherukuri, Katrina Briggs, Chitta Ranjan Patra, Mark Upton, Elisa Dolson and Priyabrata Mukherjee

abstract full text]

"I was pretty excited when the targeting happened," said Steven Curley, M.D., principal investigator for the Kanzius Project at M.D. Anderson Cancer Center in Houston. "It proves that this has the potential to work, and that it makes sense for us to continue pushing."

The published article is important because it gives the results scientific validity. Scientific journals including JETO contain articles that have been peer-reviewed to meet standards of quality.

The Kanzius Project has gained worldwide attention in the past 12 months. It has been featured on "60 Minutes" and CNN, and written about in major newspapers such as the Los Angeles Times.

The device works by sending radio waves into the body, which heat nanoparticles -- microscopic pieces of gold or carbon -- hot enough to kill the cancer cells in which they are placed.

But the biggest obstacle -- what Curley has called the "so what" question -- has been whether researchers can send the nanoparticles only to the desired cancer cells.

"This paper shows that we can target the surface of certain cancer cells," Curley said.

Curley and his research team did it by linking specific antibodies, or proteins, to the nanoparticles. The antibodies attach to the surface of certain cancer cells and are absorbed, but they don't attach to healthy cells.

Researchers tested pancreatic and colorectal cancer cells that easily absorb a particular antibody, cetuximab. They also used breast cancer cells that don't absorb the antibody as a control group.

Live cancer cells and the treated nanoparticles were placed in specimen dishes and allowed to incubate for 24 hours. They were then blasted with radio waves from Kanzius' device for two minutes.

The results: Nearly 100 percent of the pancreatic and colorectal cells were killed, but hardly any of the control group's cells were destroyed.

"It shows that we can target specific types of cancer," Curley said. "We're now working on other types of cancer cells, including breast, liver, prostate, leukemia and ovarian."

Curley said that he expects to finish writing "six to eight" more scientific manuscripts about Kanzius' device by mid-2009.

One of those papers is expected to be about tests done on blood samples involving Erie-area patients with blood cancers, such as leukemia, lymphoma and myeloma.

Blood samples were collected at the Regional Cancer Center earlier this year and treated with the RF device to determine if the radio waves killed all the cancer cells without harming healthy ones.

"We received the data, though it was a bit fragmented," Curley said. "The results are interesting, but we need more studies."

In addition to writing papers, Curley and his staff are conducting animal tests with Kanzius' device.

They hope to get approval from the Food and Drug Administration to begin human trials by late 2010. If human trials are approved, Curley has promised that Phase II trials would be held at the Regional Cancer Center, 2500 W. 12th St.

"We are right on target," Curley said. "We have a staff of nine, and we're looking to expand by another five people. I'm keeping them running."

Kanzius said he is confident the device will work on humans.

"This was a big step," Kanzius said in a telephone interview from his winter home in Sanibel, Fla. "If you look at this project as a puzzle, the targeting is the last piece. It's all downhill from here."

DAVID BRUCE can be reached at 870-1736 or by e-mail.

Source

Thursday, December 18, 2008

AngioDynamics announces use of Irreversible Electroporation technology on lymph node metastasis, first lung lesion case - Quick Facts

12/18/2008 6:50 AM ET(RTTNews) - AngioDynamics Inc.(ANGO: News ) announced the use of its Irreversible Electroporation technology on a lymph node metastasis and the first lung lesion case, at The Alfred in Melbourne, Australia.

Using the NanoKnife system, Ken Thomson, Professor and Director of the Department of Radiology at The Alfred, Monash University, performed the procedures.

Thomson reported that the two patients who were treated did not report pain related to the procedures.

by RTT Staff Writer

Source

Jumbo 'nanotube' existence confirmed at Sandia/LANL nanotech center

Published on 18 December 2008, 08:10 Last Update: 55 minute(s) ago by Insciences

ALBUQUERQUE, N.M. — A jumbo nanotube, like a jumbo shrimp, sounds contradictory.

A giant lightweight carbon nanotube with good strength and electrical properties is desirable, all right. A micron-sized carbon tube is easier to exploit commercially than any (so to speak) littler nanocousin.

But is it still a nanotube?

Jianyu Huang at the joint Sandia and Los Alamos national laboratories Center for Integrated Nanotechnologies (CINT), with colleagues elsewhere, got around this problem by naming their new creation “colossal carbon tubes” in a paper published in a recent issue of Physical Review Letters.

“The structures are remarkable because they are very light, possess good electrical conductivity, and mechanical properties similar to carbon fibers,” Huang says.

Among possibilities of use are so-called textile electronics and body armor.

Because of their strange, surprising sponginess — walls of graphite-like carbon kept apart by hollow, rectangular compartments — the colossal fibrous tubes are 20 times less dense than carbon fibers, yet about the same length — in the centimeter range. And they appear to be slightly stronger — a very desirable, and until now unheard-of property in large carbon tubes.

The new form of carbon surprised leading nanotechnology researchers. MIT’s carbon technology specialist Mildred Dresselhaus was quoted in an online news article in the journal Nature: “This is a new form of carbon that was unexpected to me.”

Huang, who did the microstructure analysis confirming that the walls of such tubes consist of graphitic structure, describes the new creation as “a porous, giant, carbon fiber-like tubular structure” of diameters ranging from 40 to 100 microns. Conventional carbon nanotubes are about 10 nanometer diameter.

The material was made at Los Alamos National Laboratory. Researchers there led by Yuntian Zhu and Huisheng Peng found that heating ethylene and paraffin oil produced a carbon vapor that condensed into tubes of pure carbon tens of microns wide and up to several centimeters long. Zhu now is at North Carolina State University, and Huisheng Peng is at Tongji University in Shanghai.

Jumbo nanotube
JUMBO TUBES -- a scanning electron microscope image (left) of a huge carbon tube. Images at right depict cross-sectional view of the tube, with rectangular pore tunnels visible in its wall. (photo by Sandi/LANL Center for Integrated Nanotechnologies)
Download 300dpi 1.11MB JPEG image


Sandia is a multiprogram laboratory operated by Sandia Corporation, a Lockheed Martin company, for the U.S. Department of Energy’s National Nuclear Security Administration. With main facilities in Albuquerque, N.M., and Livermore, Calif., Sandia has major R&D responsibilities in national security, energy and environmental technologies, and economic competitiveness.

Contact: Neal Singer, nsinger@sandia.gov, (505) 845-7078

Source: Sandia

Source

(WO/2008/027578) ELECTROMAGNETIC DEVICE AND METHOD

Pub. No.:
WO/2008/027578
International Application No.:
PCT/US2007/019246
Publication Date:06.03.2008 International Filing Date:31.08.2007
IPC: G02B 5/10 (2006.01), F21V 7/00 (2006.01)
Applicants:SEARETE LLC [US/US]; 1756-114TH Ave. SE, Suite 110, Bellevue, Washington 98004 (US) (All Except US).
HILLIS, Daniel, W. [US/US]; (US) (US Only).
HOOD, Leroy, E. [US/US]; (US) (US Only).
HYDE, Roderick, A. [US/US]; (US) (US Only).
LEUTHARDT, Eric, C. [US/US]; (US) (US Only).
MYHRVOLD, Nathan, P. [US/US]; (US) (US Only).
TEGREENE, Clarence, T. [US/US]; (US) (US Only).
WOOD, Lowell, L., Jr. [US/US]; (US) (US Only).
Inventors:HILLIS, Daniel, W.; (US).
HOOD, Leroy, E.; (US).
HYDE, Roderick, A.; (US).
LEUTHARDT, Eric, C.; (US).
MYHRVOLD, Nathan, P.; (US).
TEGREENE, Clarence, T.; (US).
WOOD, Lowell, L., Jr.; (US).
Agent:TEGREENE, Clarence, T.; c/o SEARETE LLC, 1756 114th Ave SE, Suite 110, Bellevue, Washington 98004 (US).
Priority Data:
11/515,412
31.08.2006
US
11/731,788
30.03.2007
US
Title: ELECTROMAGNETIC DEVICE AND METHOD
Abstract:
Embodiments include an apparatus, a medical device, a method and a system. The medical device includes an ellipsoidally shaped reflector having a first focus and a second focus. The ellipsoidally shaped reflector also provides a translational coupling of electromagnetic energy from the first focus to the second focus. The medical device also includes a controllable electromagnetic energy source aligned to emit a non-biologically emitted electromagnetic energy in a proximity to the first focus.

Source

Sunday, December 14, 2008

Cells used as vectors to carry materials to tumors, infection sites or other tissue sites

Cells used as vectors to carry materials to tumors, infection sites or other tissue sites by Monica Tele

Published 11/25/2008

 Cells  vectors tumors infection sites


MIT engineers have outfitted cells with tiny "backpacks" that could allow them to deliver chemotherapy agents, diagnose tumors or become building blocks for tissue engineering.

Michael Rubner, director of MIT's Center for Materials Science and Engineering and senior author of a paper on the work that appeared online in Nano Letters on Nov. 5, said he believes this is the first time anyone has attached such a synthetic patch to a cell.

The polymer backpacks allow researchers to use cells to ferry tiny cargoes and manipulate their movements using magnetic fields. Since each patch covers only a small portion of the cell surface, it does not interfere with the cell's normal functions or prevent it from interacting with the external environment.

"The goal is to perturb the cell as little as possible," said Robert Cohen, the St. Laurent Professor of Chemical Engineering at MIT and an author of the paper.

The researchers worked with B and T cells, two types of immune cells that can home to various tissues in the body, including tumors, infection sites, and lymphoid tissues � a trait that could be exploited to achieve targeted drug or vaccine delivery.

"The idea is that we use cells as vectors to carry materials to tumors, infection sites or other tissue sites," said Darrell Irvine, an author of the paper and associate professor of materials science and engineering and biological engineering.

Cellular backpacks carrying chemotherapy agents could target tumor cells, while cells equipped with patches carrying imaging agents could help identify tumors by binding to protein markers expressed by cancer cells.

Supporting Information for Synthetically Functionalized Living Cells

Intellectual Ventures - Searete - Bill Gates


Click pic to ENLARGE


Source

Intellectual Ventures is an invention company...
We conceive and patent our own inventions in-house...
...through a renowned staff of internal and external scientists and engineers.
We also acquire and license patented inventions from other inventors around the world.
Our network of invention sources includes: large and small businesses, governments, academia, and individual inventors.
These inventions span a diverse range of technologies including: software, semiconductors, wireless, consumer electronics, networking, lasers, biotechnology, and medical devices.
Our current focus is on developing our invention portfolio. Over time, we intend to market our portfolio on a broad and non-exclusive basis through a variety of channels including spin-out companies.

Source


Friday, December 12, 2008

HP flexible, unbreakable TFT display demonstrated

Friday, Dec 12th 2008 by Chris Davies

HP and Arizona State University have demonstrated what they’re calling the first prototype of “affordable, flexible electronic displays”. Constructed using the self-aligned imprint lithography (SAIL) technology invented by HP Labs, the display also uses E Ink’s Vizplex bi-stable electrophoretic imaging film that requires no power to maintain an image; the end result is a low-power, low-manufacturing-cost display suitable for color text and graphics.

hp_arizona_state_flexible_sail_display-480x386

Rather than being produced in sheets, in a batch process, SAIL allows the different layers to be combined in a roll-to-roll process. That continuous build reduces manufacturing complexity and material usage (up to 90-percent less materials by volume, in fact) and thus cost. It’s also being called “unbreakable”, with the patterning information imprinted in such a way that distortion does not impact perfect alignment.

HP envisage the new display technology to be used in laptops, smartphones and other electronic devices. Not only will form factors be able to change, thanks to the flexible screen, but the could be cheaper, too.

Press Release:

HP and Arizona State University Demo Flexible, Unbreakable Displays

Summary - HP and the Flexible Display Center (FDC) at Arizona State University (ASU) today announced the first prototype of affordable, flexible electronic displays.

Flexible displays are paper-like computer displays made almost entirely of plastic. This technology enables displays to become easily portable and consumes less power than today’s computer displays. Popular applications for the technology could include electronic paper and signage.

The production feat is a milestone in the industry’s efforts to create a mass market for high-resolution flexible displays. Plus, from an environmental standpoint, the displays leapfrog conventional display processes by using up to 90 percent less materials by volume.

Mass production of such displays can enable production of notebook computers, smart phones and other electronic devices at much lower costs since the display is one of the more costly components.

The unbreakable displays were created by the FDC and HP using self-aligned imprint lithography (SAIL) technology invented in HP Labs, HP’s central research arm. SAIL is considered “self aligned” because the patterning information is imprinted on the substrate in such a way that perfect alignment is maintained regardless of process-induced distortion.

SAIL technology enables the fabrication of thin film transistor arrays on a flexible plastic material in a low-cost, roll-to-roll manufacturing process. This allows for more cost-effective continuous production, rather than batch sheet-to-sheet production.

“The display HP has created with the FDC proves the technology and demonstrates the remarkable innovation we’re bringing to the rapidly growing display market,” said Carl Taussig, director, Information Surfaces, HP Labs. “In addition to providing a lower-cost process, SAIL technology represents a more sustainable, environmentally sensitive approach to producing electronic displays.”

Production of flexible displays

The first practical demonstration of the flexible displays was achieved through collaborative efforts between the FDC and HP as well as other FDC partners including DuPont Teijin Films and E Ink. To create this display, the FDC produces stacks of semiconductor materials and metals on flexible Teonex® Polyethylene Naphthalate (PEN) substrates from DuPont Teijin Films.

HP then patterns the substrates using the SAIL process and subsequently integrates E Ink’s Vizplex™ imaging film to produce an actively addressed flexible display on plastic. E Ink’s Vizplex bi-stable electrophoretic imaging film enables images to persist without applied voltage, thereby greatly reducing power consumption for viewing text.

“Producing a photolithography-free, flexible active-matrix display is an excellent example of the Flexible Display Center’s world-class development and manufacturing infrastructure,” said Shawn O’Rourke, director, Engineering, Flexible Display Center at Arizona State University. “It demonstrates how multiple industry partners can collaborate on innovative solutions, including roll-to-roll compatible technology that addresses the rapidly growing market for flexible electronics.”

“Flexible electronic displays are playing an increasingly important role in the global high-tech industry, serving as the crucial enabling technology for a new generation of portable devices, including e-readers and similar products designed to combine mobility with compelling user interfaces,” said Vinita Jakhanwal, principal analyst, Small and Medium Displays, iSuppli. “We expect the flexible display market to grow from $80 million in 2007 to $2.8 billion by 2013. The Flexible Display Center at Arizona State University is a key participant in helping to develop the technology and manufacturing ecosystem to support this market.”

HP SAIL technology is one example of the technologies available for licensing from the HP Intellectual Property Licensing Group.

Further information about DuPont Teijin Films is available at www.dupontteijinfilms.com.

About ASU Flexible Display Center

The FDC is a government–industry–academia partnership that’s advancing full-color flexible display technology and fostering development of a manufacturing ecosystem to support the rapidly growing market for flexible electronic displays. FDC partners include many of the world’s leading providers of advanced display technology, materials and process equipment. The FDC is unique among the U.S. Army’s University centers, having been formed through a 10-year cooperative agreement with Arizona State University in 2004. This adaptable agreement has enabled the FDC to create and implement a proven collaborative partnership model with more than 20 engaged industry members, and to successfully deploy world-class wafer-scale R&D and GEN-II display-scale pilot production lines for rapid flexible display technology development and manufacturing supply chain commercialization. More information about FDC is available at http://flexdisplay.asu.edu/.

About HP

HP, the world’s largest technology company, simplifies the technology experience for consumers and businesses with a portfolio that spans printing, personal computing, software, services and IT infrastructure. More information about HP (NYSE: HPQ) is available at http://www.hp.com/.

Source

Thursday, December 11, 2008

APNT - 2009 Baseline Forecast

(Click pic to enlarge)

And that "13.0" is very conservative and if some things DO transpire it could be MUCH higher! For example:
Higher math:

13-7=6M earnings/110M=5¢/sh X 50=$2.50/sh.(I'll be ~ even!)

20-7=13M earnings/110M=12¢/sh X 50=$6.00/sh. (I'll be living in a warm climate!)

And all that is BEFORE our nanoinks are used to tatoo the next cellphone on your forearm! And you know where the battery goes!(Don't ask!)

Wednesday, December 10, 2008

Applied Nanotech Releases Unique Heat Sink Material



CarbAl material is a carbon-based metal nanocomposite (CAl) comprised of 80 percent carbonaceous matrix and a dispersed metal component of 20 percent aluminum. The carbonaceous material is comprised of an isotropic thermally conductive carbonaceous matrix and additional anisotropic thermally conductive carbonaceous matter. The combination of the two carbonaceous phases achieves partial directionality whereby the heat is diffused in a preferred direction.

The high spcific heat may contribute to a large thermal conductivity yet expresses the potential of a large heat storage capacity that may be detrimental for heat sink applications. A large thermal diffusion coefficient will allow rapid diffusion of heat from the point of creation to a dissipative heat sink.

The new highly heat transmissive CarbAl material can be provided in rectangular blocks and other shapes based on form factor requirements of an application. The material is not hard and can be sliced easily to very thin samples that interface between the local point of heat creation and a heat sink or other heat dissipative device.

The new CarbAl heat sink material is a nanocomposite of a carbonaceous type of material and aluminum. The aluminum content is only 20 percent, while the thermal transmission of the new material is approaching 500 W/mK (for comparison aluminum thermal conductivity is 203 and copper is 390).

Source (p7)

Tuesday, December 9, 2008

Nano-magnetic sensors could pave the way for massive data storage capacity

Trendwatch
By Rick C. Hodgin
Tuesday, December 09, 2008 14:25

Troy (NY) - Researchers at Rensselaer Polytechnic Institute (RPI) have created nanoscopic magnetic sensors. Comprised of carbon nanotubes embedded with bundles of cobalt atoms, these magnetic field sensors are the first ever capable of reliably detecting magnetic fields at near atomic levels.

RPI is calling its discovery "a new class of magnetic materials." The nano-device's cobalt clusters are embedded within the walls of a multi-layered carbon nanotube, just 1 nm to 10 nm in diameter. Since the clusters are internal to the tubes, rather than external, "they do not cause electron scattering and thus do not seem to impact the attractive conductive properties of the host carbon nanotube," according to assistant professor Swastik Kar, Department of Physics, who led the project.

A series of experiments has shown that the cobalt-cluster carbon nanotubes are sensitive enough to detect even miniscule magnetic fields present at near-atomic levels. RPI believes this is the first time such small magnetic fields have been reliably detected using carbon nanotubes, and it provides a new tool for analyzing the nanoscopic magnetic properties of many everyday items - something that was not possible previously due to an interference of the source materials used in the detector.


Future applications

According to the research paper, potential future applications include "new generations of nanoscale conductance sensors, new advances in digital storage devices, spintronics, and selective drug delivery components." Today's most advanced perpendicular storage techniques allow up to around 200 Gb of data per square inch (25 Gigabytes). Hard drives on the order of 10 nm per bit would allow upwards of 10 Petabits (Pb) per square inch - though realistic applications would be closer to 100 Terabits per square inch. Perpendicular storage solutions are expected to max out around 1 Terabit per square inch, though this ceiling appears to be constantly moving.

Today, semiconductors companies often utilize infrared emissions to detect electron movement through silicon-based transistors. TG Daily had the opportunity to visit Intel's debug lab in Nov, 2007. The laser probes used in that lab detect the emission of infrared light, which is transparent to silicon, and seeps through the back of the chip while the CPU is running.

By monitoring photon activity on the chip with the laser probe, the CPU debuggers can isolate individual circuits in operation. This helps them detect errors for chip designers and track down other problems or inefficiencies. This new RPI device may also produce an alternate method for detecting this kind of circuit activity.

The results of this study were published in an article entitled "Detection of Nanoscale Magnetic Activity Using a Single Carbon Nanotube" in Nano Letters.


Funding

Funding for this project was provided by the New York State Interconnect Focus Center at Rensselaer. Additional authors on the Nano Letters paper include Caterina Soldano, a postdoctoral research assistant at the Centre d’Elaboration de Matériaux et d’Etudes Structurales in Tolouse, France. Also, Professor Saikat Talapatra of the Physics Department of Southern Illinois University-Carbondale. And Professor P.M. Ajayan of Rice University's Department of Mechanical Engineering and Materials Science.


Other research

Additional recent carbon nanotube-related research from RPI includes a nanoscopic pressure sensor made of carbon nanotubes. RPI has also recently developed a solar cell coating which allows panels to absorb 90% of sunlight without the need for servos which track the sun's movement across the sky.

Source

Monday, December 8, 2008

Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques

Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques
MA Wozniak 1, AP Mee 2 a, RF Itzhaki 1 *
1Faculty of Life Sciences, University of Manchester, UK
2Department of Medicine, Manchester Royal Infirmary, UK
email: RF Itzhaki (ruth.itzhaki@manchester. ac.uk)

*Correspondence to RF Itzhaki, Faculty of Life Sciences (North Campus), Moffat Building, University of Manchester, PO Box 88, Manchester M60 1QD, UK.

aCurrent address: Directorate of Laboratory Medicine, CMMC, Oxford Road, Manchester M13 9PL, UK

No conflicts of interest were declared.
Keywords
brain • Alzheimer's disease • herpes simplex encephalitis • herpes simplex virus type 1 • amyloid plaques • apolipoprotein E • in situ polymerase chain reaction • thioflavin S staining • immunohistochemistry
Abstract
The brains of Alzheimer's disease sufferers are characterized by amyloid plaques and neurofibrillary tangles. However, the cause(s) of these features and those of the disease are unknown, in sporadic cases. We previously showed that herpes simplex virus type 1 is a strong risk factor for Alzheimer's disease when in the brains of possessors of the type 4 allele of the apolipoprotein E gene (APOE-4), and that -amyloid, the main component of plaques, accumulates in herpes simplex virus type 1-infected cell cultures and mouse brain. The present study aimed to elucidate the relationship of the virus to plaques by determining their proximity in human brain sections. We used in situ polymerase chain reaction to detect herpes simplex virus type 1 DNA, and immunohistochemistry or thioflavin S staining to detect amyloid plaques. We discovered a striking localization of herpes simplex virus type 1 DNA within plaques: in Alzheimer's disease brains, 90% of the plaques contained the viral DNA and 72% of the DNA was associated with plaques; in aged normal brains, which contain amyloid plaques at a lower frequency, 80% of plaques contained herpes simplex virus type 1 DNA but only 24% of the viral DNA was plaque-associated (p < src="http://www3.interscience.wiley.com/giflibrary/12/beta.gif" align="absbottom" border="0">-amyloid (A), so that less of the viral DNA is seen to be associated with A in the brain. Our present data, together with our finding of A accumulation in herpes simplex virus type 1-infected cells and mouse brain, suggest that this virus is a major cause of amyloid plaques and hence probably a significant aetiological factor in Alzheimer's disease. They point to the usage of antiviral agents to treat the disease and possibly of vaccination to prevent it. Copyright © 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Received: 24 June 2008; Revised: 6 August 2008; Accepted: 5 September 2008
Digital Object Identifier (DOI)

10.1002/path.2449 About DOI

Source

Article on this discovery from The Washington Post:

Cold Sore Virus Linked to Alzheimer's

People who develop cold sores may be at increased risk for Alzheimer's disease, according to British researchers who said the herpes virus that causes cold sores is a major cause of the brain protein plaques associated with Alzheimer's.

The University of Manchester team found DNA evidence of the herpes simplex virus (HSV) type 1 in 90 percent of plaques in Alzheimer's patients'brains, BBC News reported. The findings were published in the Journal of Pathology.

"We suggest that HSV1 enters the brain in the elderly as their immune systems decline and then establishes a dormant infection from which it is repeatedly activated by events such as stress, immunosuppression, and various infections," said Professor Ruth Itzhaki. This causes damage to brain cells, which die and disintegrate, releasing the proteins that form the plaques that cause Alzheimer's, the study suggested.

The potential good news in this study is that antiviral drugs used to treat cold sores may also prevent dementia. Itzhaki and colleagues plan to test that theory, BBC News reported.



Sunday, December 7, 2008

Virus hunter looks to make more medical breakthroughs at UCSF

Joe DeRisi and his "ViroChip" will be vital components of a new center for viral diagnosis and discovery at UC San Francisco.

Joe DeRisi sometimes pays a peculiar price for fame.

The man who invented the virus-seeking "ViroChip," who helped identify the cause of SARS and who won a MacArthur "genius" award in pursuit of the secrets of infection has become a magnet for medical mysteries.

Every month or so, someone gets past security, up the gleaming stairways of UC San Francisco's Genetech Hall, and into DeRisi's lab with the same distraught demand: Test me.

DeRisi gently sends them away. He runs a research lab, not a clinic.

It has been harder, however, for DeRisi to sift through the barrage of fascinating calls and e-mails from doctors, veterinarians, hospitals and other researchers.

"We get requests for (testing) cancers all the time … any type of cancer you could imagine" that might be caused by a virus, DeRisi said. "It's been a little disappointing that we haven't been able to do more."

That could change early next year, when UCSF launches a center for viral diagnosis and discovery. Its ambition is to hunt down more causes of pneumonia, encephalitis and other lethal and disabling conditions whose origins too often baffle doctors, even as their patients are slipping away.

"Our plan is: Make it open to everybody," from doctors with a single troubling case to large research efforts such as the state-run California Enchephalitis Project, said Dr. Charles Chiu, an infectious disease specialist who'll head the center.

DeRisi will be an adviser, and his ViroChip, a microarray that holds genetic snippets of thousands of viruses on one glass slide, will be one of the key sleuthing tools.

The center is just the latest spinoff of a passion for pathogens that has taken DeRisi from a childhood in Carmichael to scientific renown.

"I'm really interested in pathogens that make other things ill," he said. "This ongoing battle between host and invader … including different countermeasures, counter-countermeasures, evasive tactics, stealth systems. It's amazing."

He was speaking last week in an office cluttered with stacks of scientific journals, a tangle of computers and a martial arts punching bag.

The conversation ricocheted from calligraphy to computer programming, from Del Campo High School – "a great public school education" – to his childhood paper route – "a rip-off job."

Those were only detours from his career's two main research tracks: malaria and the army of viruses that attack people, parrots or bees.

"Joe has a very high-energy personality. This guy is on 30,000 volts all the time," said Dr. Don Ganem, a UCSF professor of medicine and microbiology who has collaborated with DeRisi on several virus hunts.

"He's a phenomenal intellect …" Ganem said, "in a league with only a few other people in the world, many of whom have already won the Nobel Prize."

Oh, and DeRisi is not yet 40.

Slight and curly-haired, DeRisi has a cell phone packed with photos of his 5-month-old and 3-year-old daughters and fond memories of the tandem mountain bike he and his wife have mostly abandoned in favor of parenthood.

He grew up water-skiing on Folsom Lake, dabbling in school science experiments, commercial art and computers. In the sixth grade, he started to program, for fun.

He fled the Sacramento Valley heat to attend UC Santa Cruz and Stanford, where he immersed himself in jujitsu and biochemistry and began his fascination with malaria.

"It is not a disease of the first world," DeRisi said of the mosquito-borne parasite estimated to kill 1 million or more people each year. "It is not a disease in which there's large corporate interests. There's no profit to be made. … It wasn't really getting the kind of attention that it deserved."

As a doctoral student, he'd been working on tracking activity of thousands of genes at a time. He later trained that tool on malaria, publishing a landmark analysis of its genetic activity during its proliferation in the human bloodstream.

Since then, DeRisi has collaborated with others looking for weak links in the parasite's basic biology, anything that a new drug might be able to attack or exploit. If one potential treatment lives up to its early promise, it could be a couple of years away from testing in humans.

While immersed in malaria, DeRisi also has written software, built robots and created devices that have made possible broader virus testing, including his 2003 detection of the virus responsible for severe acute respiratory syndrome, or SARS. Often, he posts methods and findings on his Web site or publishes in open-access journals that don't demand costly subscription fees.

"He's incredibly generous," said Chiu, "a very big fan of open-source publishing, making scientific data available to researchers everywhere."

Chiu hopes the same spirit of openness will be a key part of the viral discovery and diagnosis center that will rely on DeRisi's ViroChip, and other detective techniques, to hunt new causes of age-old ills.

"About 20 to 30 percent of the time we can't make a diagnosis in pneumonia," said Chiu. "The situation is even worse for other severe diseases like encephalitis," an inflammation of the brain whose cause is unknown in more than 60 percent of cases.

Those mysteries are "unbelievably frustrating to the family, the patients … the physicians," said Dr. Carol Glaser, who is involved in a government-funded effort to detect more causes of encephalitis.

"If you don't know what causes it, how can you figure out how to treat it or prevent it?" she said.

Eliminating a wide range of possible causes can protect a desperately ill person from undergoing risky diagnostic tests or taking unneeded drugs.

Once the new center is up and running, perhaps in February or March, Chiu expects to hear from more doctors struggling to understand unusual cases, the ones where patients keeps getting sicker and all the standard diagnostic tests come back negative.

Still, said DeRisi, "We don't want members of the public sending us weird stuff. We want them to go to their doctor and have the doctor send us stuff. "


Call The Bee's Carrie Peyton Dahlberg, (916) 321-1086.

Source

Tuesday, December 2, 2008

Full body IRE

These articles are informative of the state of the IRE art:

Engineers Destroy Cancer Cells

August 01, 2007

A team of biomedical engineers at Virginia Tech and the University of California at Berkeley has developed a new minimally invasive method of treating cancer, and they anticipate clinical trials on individuals with prostate cancer will begin soon.

The process, called irreversible electroporation (IRE), was invented by two engineers, Rafael V. Davalos, a faculty member of the Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences and Boris Rubinsky, a bioengineering professor at the University of California, Berkeley.
http://www.vaeng.com/news/engineers-destroy-cancer-cells


Irreversible Electroporation
Guest Editor: Boris Rubinsky, Ph.D.
Irreversible Electroporation in Medicine (p. 255-260)

TCRT August 2007
Volume 6
No. 4 (p 255-360)
August 2007
ISSN 1533-0338
Open Access

Abstract
This is a brief introduction to the emerging field of irreversible electroporation in medicine. Certain electrical fields when applied across a cell can have as a sole effect the permeabilization of the cell membrane, presumable through the formation of nanoscale defects in the cell membrane. Sometimes this process leads to cell death, primarily when the electrical fields cause permanent permeabilization of the membrane and the consequent loss of cell homeostasis, in a process known as irreversible electroporation. This is an unusual mode of cell death that is not understood yet. While the phenomenon of irreversible electroporation may have been known for centuries it has become only recently rigorously considered in medicine for various applications of tissue ablation. A brief historical perspective of irreversible electroporation is presented and recent studies in the field are discussed.
http://www.tcrt.org/index.cfm?d=3029&c=4...


Design of an Irreversible Electroporation System for Clinical Use (p. 313-320)

TCRT August 2007
Volume 6
No. 4 (p 255-360)
August 2007
ISSN 1533-0338
Open Access Article

Abstract
Irreversible electroporation is an ablation modality in which microseconds, high-voltage electrical pulses are applied to induce cell necrosis in a target tissue. To perform irreversible electroporation it is necessary to use a medical device specifically designed for this use.

The design of an irreversible electroporation system is a complex task in which the effective delivery of high energy pulses and the safety of the patient and operator are equally important. Pulses of up to 3000 V of amplitude and 50 A of current need to be generated to irreversibly electroporate a target volume of approximately 50 to 70 cm3 with as many as six separate electrodes; therefore, a traditional approach based on high voltage amplifiers becomes hard to implement.
http://www.tcrt.org/index.cfm?d=3029&c=4...

Comments:
It seems that only pulsed high voltage electric current has been investigated for use in IRE. Leads me to think that other energy sources such as radio frequency, xray and focused beams of all kinds should be investigated as IRE candidates.

Full body IRE

A full (or part) body IRE body conforming set(s) of opposing electrodes. Would that be feasible, wise, workable?

A tip to toe body sized form fitting electrode assembly covering front and back and sides encompassing the entire body with appropriate IRE pulses fed to the body parts involved with cancer that would zap cancer cells and kill them.

Or a portion of a human body encompassing arrangement at the wrist, for example, to zap the flowing blood and zapping the leukemia cancer cells flowing therethrough until all are killed.

I know Kanzius is doing just this with high frequency radio waves acting on nanoparticles in the body attached to cancer cells and killing those cancer cells heated to death by the radio wave energy attracted to the nanoparticles and transferred to the attached cancer cells.

This whole body (or part thereof) IRE device I propose would give the same result (subject to verification, of course, I am only proposing here) - cancer cell death - but without the need for any nanoparticles or needles.

Ref:
Kanzius
http://donpatent.blogspot.com/search?q=Kanzius

Just a thought!

Something simple, painless and effective. And quick.

Now all we need is someone to build and test it.

Inovio (INO)!!??


Monday, December 1, 2008

Carbon Nanotubes Detect Lung Cancer Markers in the Breath

November 2008

Using an array of nanotube devices, each coated with a different organic material, researchers at the Israel Institute of Technology have developed diagnostic system that may be able to diagnose lung cancer simply by sampling a patient’s breath. The results of this study, which was led by Hossam Haick, Ph.D., appear in the journal Nano Letters.

Dr. Haick and his collaborators first created individual devices consisting of random networks of single-walled carbon nanotubes coated with 1 of 10 different insulating nonpolymeric organic materials. The investigators used standard microprocessor fabrication techniques to create the sensors. Thanks to the different organic materials used to coat the nanotubes, each sensing device provided a unique response when exposed to wide variety of the more than 200 volatile organic chemicals present in human breath.

To calibrate the devices, the investigators captured the breath of 15 nonsmoking healthy patients and 15 individuals with stage 4 lung cancer. Next, they concentrated the organic compounds in each breath sample using a method known as solid phase microextraction and then analyzed each sample using gas chromatography-mass spectrometry (GC-MS). GC-MS is a highly accurate technique that is too expensive and time consuming to find use as a routine diagnostic assay. The researchers then ran the same samples through their sensor array; the electrical output of the test devices changed in a way that was characteristic of the exact mixture of organic compounds found in the breath samples.

From these data, the investigators were able to distinguish between two response patterns from each of the 10 array members. There was no overlap in the response patterns between the healthy and lung cancer patients in these first tests. The researchers are now testing their system on a much larger group of patients and healthy subjects.

This work is detailed in the paper “Detecting simulated patterns of lung cancer biomarkers by random network of single-walled carbon nanotubes coated with nonpolymeric organic materials.” An abstract of this paper is available at the journal’s Web site.

http://nano.cancer.gov/news_center/2008/nov/nanotech_news_2008-11-20c.asp

I checked 2 of APNT's patent filings - CLOSE!:

1) United States Patent Application 20070167832
Kind Code A1
Yaniv; Zvi ; et al. July 19, 2007
Analysis of Gases

Abstract

Systems and techniques for the analysis of gases for medical purposes are described. In one aspect, a system includes a sample collector to collect a physical sample associated with an individual and present a gas sample for analysis, a gas analysis device to analyze the gas sample presented by the sample collector to determine a concentration of one or more non-aqueous gases in the gas sample, a data storage device that includes information reflecting a correlation between concentration of the one or more non-aqueous gases in the gas sample and a disease state, and a data analysis device to determine a medical condition of the individual based on the concentration of one or more non-aqueous gases in the gas sample and the information.

Inventors: Yaniv; Zvi; (Austin, TX) ; Soundarrajan; Prabhu; (Austin, TX)
Source

2) United States Patent Application 20050244811
Kind Code A1
Soundarrajan, Prabhu ; et al. November 3, 2005
Matrix array nanobiosensor

Abstract

An apparatus for detecting multiple analytes comprising an array of nanobiosensors, each comprising a biological entity immobilized onto carbon nanotubes, wherein a plurality of the nanobiosensors in the array have unique biological entities, wherein a first one of the plurality of nanobiosensors has a first biological entity immobilized onto carbon nanotubes, and wherein a second one of the plurality of nanobiosensors has a second biological entity immobilized onto carbon nanotubes, the first biological entity is unique relative to the second biological entity.

Inventors: Soundarrajan, Prabhu; (Austin, TX) ; Ginsberg, Valerie; (Austin, TX) ; Yaniv, Zvi; (Austin, TX)
Source

Targeted Nanoparticles Boost Platinum-Based Anticancer Therapy

A research team from the Massachusetts Institute of Technology (MIT)-Harvard Center for Nanotechnology Excellence has custom-designed nanoparticles that can deliver the anticancer drug cisplatin specifically to prostate cancer cells. The nanoparticles are composed of two different polymers and are decorated with a nucleic acid aptamer that binds to the tumor marker prostate-specific membrane antigen. This aptamer ensures that the nanoparticles deliver their payload only to prostate cancer cells.

Stephen Lippard, Ph.D., and Robert Langer, Ph.D., MIT, and Omid Farokhzad, M.D., Harvard Medical School, led the team that developed this new formation of cisplatin. The investigators published their results in the Proceedings of the National Academy of Sciences of the United States of America.

To construct a stable nanoparticle that would only release its toxic cargo inside tumor cells, the investigators synthesized a modified version of cisplatin that includes a long hydrocarbon chain. As the nanoparticle forms, the hydrocarbon chain associates strongly with the hydrophobic chains of the polymer that forms the nanoparticle’s core. The researchers note that the hydrocarbon chain they chose optimizes both drug encapsulation and drug release inside tumor cells. Once the nanoparticle enters the cell, the modified drug is converted into its active form as a result of chemical conditions inside the cell.

Tests with human cancer cells growing in culture showed that these nanoparticles were taken up specifically by tumor cells and not by healthy cells. Nanoparticles lacking the targeting aptamer were not taken up either. These tests also demonstrated that the nanoparticles release their cargo over the course of 60 hours, providing a sustained lethal level of the drug inside the targeted cells. In addition, the nanoparticle formulation was approximately 100 times more effective at killing tumor cells than was cisplatin by itself.

This work, which is detailed in the paper “Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles,” was supported by the NCI Alliance for Nanotechnology in Cancer, a comprehensive initiative designed to accelerate the application of nanotechnology to the prevention, diagnosis, and treatment of cancer. An abstract of this paper is available at the journal’s Web site.

View abstract

Source